<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE collection SYSTEM "BioC.dtd">
<collection><source>PMC</source><date>20201214</date><key>pmc.key</key><document><id>30714</id><infon key="license">NO-CC CODE</infon><passage><infon key="article-id_pmc">30714</infon><infon key="article-id_pmid">11299067</infon><infon key="article-id_publisher-id">CC-5-2-088</infon><infon key="fpage">88</infon><infon key="issue">2</infon><infon key="journal-title">Critical Care</infon><infon key="kwd">artificial pancreas coagulopathy diabetes 
mellitus multiple organ dysfunction syndrome tissue 
plasminogen activator-plasminogen activator inhibitor-1 complex</infon><infon key="lpage">99</infon><infon key="name_0">surname:Hoshino;given-names:Masami</infon><infon key="name_1">surname:Haraguchi;given-names:Yoshikura</infon><infon key="name_2">surname:Hirasawa;given-names:Hiroyuki</infon><infon key="name_3">surname:Sakai;given-names:Motohiro</infon><infon key="name_4">surname:Saegusa;given-names:Hiroshi</infon><infon key="name_5">surname:Hayashi;given-names:Kazushiro</infon><infon key="name_6">surname:Horita;given-names:Naoki</infon><infon key="name_7">surname:Ohsawa;given-names:Hiroyuki</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="volume">5</infon><infon key="year">2001</infon><offset>0</offset><text>Close relationship of tissue plasminogen activator-plasminogen  activator inhibitor-1 complex with multiple organ dysfunction syndrome  investigated by means of the artificial pancreas</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>185</offset><text>Background:</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>197</offset><text>Glucose tolerance (GT) has not been taken into consideration in  investigations concerning relationships between coagulopathy and multiple organ  dysfunction syndrome (MODS), and endothelial cell activation/endothelial cell  injury (ECA/ECI) in septic patients, although coagulopathy is known to be  influenced by blood glucose level. We investigated those relationships under  strict blood glucose control and evaluation of GT with the glucose clamp method  by means of the artificial pancreas in nine septic patients with glucose  intolerance. The relationships between GT and blood stress related hormone  levels (SRH) were also investigated.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>843</offset><text>Methods:</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>852</offset><text>The amount of metabolized glucose (M value), as the parameter of  GT, was measured by the euglycemic hyperinsulinemic glucose clamp method, in  which the blood glucose level was clamped at 80 mg/dl under a continuous  insulin infusion rate of 1.12 mU/kg per min, using the artificial pancreas,  STG-22. Multiple organ failure (MOF) score was calculated using the MOF  criteria of Japanese Association for Critical Care Medicine. Regarding  coagulopathy, the following parameters were used: disseminated intravascular  coagulation (DIC) score (calculated from the DIC criteria of the Ministry of  Health and Welfare of Japan) and the parameters used for calculating DIC score,  protein-C, protein-S, plasminogen, antithrombin III (AT-III), plasminogen  activator inhibitor-1 (PAI-1), and tissue plasminogen activator-PAI-1  (tPA-PAI-1) complex. Thrombomodulin (TM) was measured as the indicator of  ECI.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1755</offset><text>Results:</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1764</offset><text>There were no significant correlations between M value and SRH,  parameters indicating coagulopathy and the MOF score. The MOF score and blood  TM levels were positively correlated with DIC score, thrombin-AT-III complex  and tPA-PAI-1 complex, and negatively correlated with blood platelet count.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>2062</offset><text>Conclusions:</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>2075</offset><text>GT was not significantly related to SRH, coagulopathy and MODS under strict  blood glucose control. Hypercoagulability was closely related to MODS and ECI.  Among the parameters indicating coagulopathy, tPA-PAI-1 complex, which is  considered to originate from ECA, seemed to be a sensitive parameter of MODS  and ECI, and might be a predictive marker of MODS. The treatment for reducing  hypercoagulability and ECA/ECI were thought to be justified as one of the  therapies for acutely ill septic patients.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>2582</offset><text>Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2595</offset><text>Hypercoagulability and decreased fibrinolysis, including increased PAI-1  level, are often found in the clinical field and are considered to be the risk  factors of cardiovascular diseases and glucose intolerance, especially in  patients with noninsulin-dependent diabetes mellitus (NIDDM) [ ,]. Most of the acutely ill  severe patients also have coagulopathy, and they often have glucose  intolerance. The relationships between coagulopathy and organ  dysfunction/glucose intolerance in the acute ill phase have not, however, been  clearly analyzed. Although there are reports investigating the relationship  between coagulopathy and organ dysfunction, and  the relationship between coagulopathy and endothelial cell activation/injury  [ ,] in septic patients, there is no report  investigating the relationship between coagulopathy and GT in septic patients  as far as we know. Moreover, parameters related to coagulopathy are known to be  influenced directly by the metabolic factors. For example, glucose, insulin,  and fat influence the production of PAI-1, which is the important parameter  related to coagulopathy [ , ,]. In aforementioned reports, however, metabolic  factors, especially blood glucose level (BG) that is usually unstable in the  septic state, are not taken into consideration.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3897</offset><text>We have been using the bedside type artificial pancreas (AP) in septic  patients with glucose intolerance since 1985 to control BG, to perform  effective nutritional support, and to evaluate metabolic disorders including  glucose and fat. By strictly stabilizing BG using AP, analyses of the factors  including PAI-1 that are influenced by BG are considered to be correctly  performed.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4283</offset><text>The purpose of this study is, first, to analyze the relationships between  coagulopathy, including abnormal blood PAI-1-related parameters, and glucose  tolerance, MODS, and endothelial cell injury. Second was to investigate which  parameters related to coagulopathy were most closely related to glucose  tolerance, MODS, and endothelial cell injury, in septic patients with glucose  intolerance in whom BG was strictly controlled and the glucose tolerance was  evaluated with the glucose clamp method by means of AP. We consider that better  understanding of the aforementioned relationships and confirming the useful  parameters will be helpful for the early diagnosis of the severity of sepsis  and for the treatment of the septic patients.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>5027</offset><text>Materials and methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5049</offset><text>The investigated patients were nine septic intensive care unit patients with  glucose intolerance in whom BG was strictly controlled by means of AP. We  selected the patients with strict blood glucose control by AP in order to  exclude the direct influence of BG to the parameters related with coagulopathy,  including PAI-1-related parameters, as already mentioned. The patients were all  in septic condition, which was defined as the condition with systemic  inflammatory response syndrome caused by the infection. To analyze the septic patients with sepsis-induced (or related)  glucose intolerance, the diabetes patients and those who had liver or  pancreatic diseases as primary diseases were excluded. Six patients had acute  respiratory distress syndrome (four caused by panperitonitis, two after  intracranial hemorrhage), two had gangrene of a lower extremity, and one had a  burn (Table 1). One patient with panperitonitis died.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5988</offset><text>Regarding administered drugs that might influence glucose tolerance on the  day when the GT measurements were performed (total number of measurements, 18  times (days); 2 times (days) for each patient; see later), dopamine was used  for 5 patients (6 days out of 10 measured days), predonisolone for 1 patient (2  days out of 2 measured days), and dobutamine for 1 patient (2 days out of 2  measured days). The amount of dopamine used was less than 5 μg/kg per min  (mean, 2.5 ± 1.6 μg/kg per min [n = 6]; all were used for  increasing renal blood flow), that of predonisolone was 40 mg/day, and that of  dobutamine was 13 and 4 μg/kg per min.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6636</offset><text>Analyzed items were as follows. Regarding MODS, the multiple organ failure  (MOF) score was calculated using the MOF criteria of the Japanese Association  for Critical Care Medicine (Table  2). The maximum of the MOF score is 14. The modified MOF score (mMOF  score), in which points of disseminated intravascular coagulation (DIC)  (coagulopathy) were excluded, was also calculated when the correlation between  coagulopathy and MODS was investigated.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7089</offset><text>The parameter of glucose metabolism, the M value (the amount of  metabolized glucose), was measured by the euglycemic hyperinsulinemic glucose  clamp method, in which the BG level was clamped (or maintained) at 80 mg/dl  under a continuous insulin infusion rate of 1.12 mU/kg per min (40 mU/m 2per min), using AP. The M value is the amount of glucose  infusion required to clamp BG, and is the indicator of peripheral glucose  tolerance (normal range, 6-8 mg/kg per min). The daily mean blood glucose level was calculated from  the BG measured (sampled) every 1 h.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7654</offset><text>The blood concentration of stress hormones (catecholamines [adrenaline,  noradrenaline, dopamine], growth hormone, glucagon, cortisol),  adrenocorticotrophic hormone, and thyroid-related hormones (thyroid stimulating  hormone, triiodothyronine [T3], free T3, thyroxine [T 4], free T4) were measured because they might influence the  GT. Dopamine, dobutamine, and predonisolone were administered when the  measurements of the M value were performed in some patients as already  mentioned.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8142</offset><text>Regarding coagulopathy, the following parameters were used: DIC score,  platelet count (PLT), fibrin and fibrinogen degradation products, fibrinogen,  prothrombin time (PT) ratio (PT of the patient divided by control PT), D-dimer,  α2 plasmin inhibitor-plasmin complex, thrombin-antithrombinIII  complex (TAT), protein C antigen and activity, protein S antigen and activity,  plasminogen, antithrombin III (AT-III), PAI-1 antigen and activity, and tissue  plasminogen activator (tPA)-PAI-1 complex. The DIC score was calculated from  the DIC criteria of the Ministry of Health and Welfare of Japan (Table 3).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8755</offset><text>As the indicator of the endothelial cell injury, the blood concentration of  thrombomodulin (TM) was measured. Fibrinogen was measured by the thrombin time  method, PT by Quick's method, and fibrin and fibrinogen degradation products by  the latex agglutination method. TAT, tPA-PAI-1 complex, protein S antigen,  protein S activity and TM were measured by enzyme immunoassay, D-dimer and  PAI-1 antigen by enzyme-linked immunosorbent assay, and α2  plasmin inhibitor-plasmin complex and protein C antigen by the Latex  photometric immunoassay. AT-III, PAI-1 activity and plasminogen were measured  by the synthetic substrate method, and protein C activity by the activated  partial thromboplastin time method (SRL Inc Co, Tokyo, Japan).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9497</offset><text>Data sampling/measurement (blood sampling, MOF/DIC scoring, and glucose  clamp method) was performed twice for each patient. The first data  sampling/measurement was carried out within 3 days after the admission, and the  second data sampling/measurement was performed 1 week after the first data  sampling/measurement. Blood sampling was carried out at 08:00 h on the day when  the glucose clamp method (the measurement of the M value) was  performed. We began the glucose clamp method at 09:00 h, when intravenous drip  infusion containing glucose for nutritional support was stopped. The daily mean  blood glucose level was calculated using the BG during 24 h before the start of  the glucose clamp method.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>10207</offset><text>The following points were investigated in turn using the aforementioned  data. First, confirmation of the capability of the AP for strict blood glucose  control (by calculating the daily mean BG) and for the evaluation of the GT  (M value). Whether the blood concentration of the stress-related  hormones (listed earlier), which are considered to be influenced by sepsis and  by the administration of drugs, was related to the GT (M value) was  also investigated. Third, whether there were any relationships between the  glucose tolerance (M value) and coagulopathy, MODS (MOF score). The  relationships among coagulopathy, MODS (MOF/mMOF score), and endothelial cell  injury (TM) were then investigated. Finally, confirmation of the parameters  related to coagulopathy that were most closely correlated with MODS (MOF/mMOF  score) and endothelial cell injury (TM).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>11073</offset><text>The AP used was STG-22, manufactured by NIKKISOH Corporation (Tokyo, Japan)  (Fig. 1). The AP controls BG by administering insulin or  glucose automatically according to the absolute BG and the change of BG, which  is measured by continuous blood sampling.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>11330</offset><text>The statistical data are shown as mean ± standard deviation. Strengths  of the relationships between the data are indicated by correlation coefficient  r, and the correlations between the data are shown by a regression  line. The unpaired Student t test was used for the comparison of mean  values. P &lt; 0.05 was considered significant.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>11667</offset><text>Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>11675</offset><text>Blood glucose control and measurements of the glucose tolerance by  means of AP</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>11755</offset><text>The mean of the daily mean blood glucose levels and M values  obtained from the first and second measurements were 183 ± 32 mg/dl ( n = 8), 4.4 ± 1.4 mg/kg per min (n = 7), and 147 ± 26  mg/dl (n = 9), 4.7 ± 1.6 mg/kg per min (n = 8),  respectively (Table 4). The daily mean blood glucose  level could not be calculated in one patient at the first measurement because a  blood sampling disorder of AP occurred and a sufficient number of BG data could  not be obtained. M values could also not be measured in two patients  at the first measurement and in one patient at the second measurement because  the glucose intolerance was severe and the BG level did not decrease to the  clamp level (80 mg/dl).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>12461</offset><text>No significant relationships between the GT and blood stress  related hormone levels</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>12546</offset><text>There were no significant correlations between the M value and  blood stress hormone levels (adrenaline, noradrenaline, dopamine, growth  hormone, glucagon, cortisol), adrenocorticotrophic hormone, and thyroid-related  hormones (thyroid stimulating hormone, T3, free T3, T 4, free T4) (Table 5). We also  investigated whether drug (catecholamines [dopamine, dobutamine],  glucocorticoids [predonisolone]) administration significantly influenced the  glucose tolerance. There was, however, no significant difference between the  mean of the M values of the patients who were administered those drugs  (4.9 ± 1.3 mg/kg per min; n = 10) and that of those who were not  administered those drugs (4.0 ± 1.7 mg/kg per min; n = 5).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>13273</offset><text>No significant correlations between the GT and MODS,  coagulopathy</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>13340</offset><text>There were no significant correlations between the M value and  MODS, and parameters related to coagulation and fibrinolysis (Table 6).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>13476</offset><text>Significant correlation between coagulopathy and MODS</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>13530</offset><text>The MOF score was strongly correlated with the DIC score (r = 0.75,  P &lt; 0.002), TAT (r = 0.72, P &lt; 0.002),  tPA-PAI-1 complex (r = 0.69, P &lt; 0.002) and PLT ( r = -0.68, P &lt; .002) among parameters related with  coagulation and fibrinolysis (Table 7). Because three of  the aforementioned parameters (not the tPA-PAI-1 complex) are used for  calculating the MOF score, however, correlations between the mMOF score, in  which the points of coagulopathy of the MOF score are excluded, and parameters  related to coagulation and fibrinolysis were also analyzed. The mMOF score was  still strongly correlated with TAT (r = 0.69, P &lt; 0.002),  DIC score (r = 0.66, P &lt; 0.002), PLT (r = -0.65,  P &lt; 0.003) and tPA-PAI-1 complex (r = 0.62, P  &lt; 0.005) (Table 8; Fig. 2).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>14292</offset><text>Significant correlations between endothelial cell injury and MODS,  coagulopathy</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>14373</offset><text>TM was correlated with MOF score (r = 0.92, P &lt;0.002)  (Fig. 3), DIC score (r = 0.80, P &lt;  0.002), tPA-PAI-1 complex (r = 0.85, P &lt; 0.002), TAT ( r = 0.85, P &lt; 0.002) and PLT (r = -0.58, P  &lt; 0.03) (Table 9; Fig. 4). In  one patient, the measurement of TM was performed only once.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>14654</offset><text>Relationships between tPA-PAI-1 complex and other parameters  related to coagulation and fibrinolysis</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>14756</offset><text>The tPA-PAI-1 complex was positively correlated with DIC score (r =  0.74, P &lt; 0.002), TAT (r = 0.85, P &lt; 0.002),  and PAI-1 antigen (Table 10).</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>14901</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>14912</offset><text>Acutely ill patients often have coagulopathy and metabolic disorders,  including glucose intolerance and abnormal serum fat levels, as well as organ  dysfunctions. Those abnormalities seem to be mutually related, but studies  concerning relationships among coagulopathy, metabolic disorders, and organ  dysfunctions have rarely been reported. One of the reasons for this lack of  literature seems to be that metabolic disorders, especially glucose  intolerance, are unstable and could not be easily evaluated in acute phase. In  this study, we have investigated those relationships under strict blood glucose  control and the strict evaluation of the GT with the glucose clamp method by  means of AP in septic patients with glucose intolerance.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>15657</offset><text>Although the glucose tolerances of the patients were impaired, blood glucose  control by means of AP was good, considering results of the mean of the  M values and the daily mean BG (Table 4). We could  not measure the M value three times because the GT was so severe that  BG did not decrease to the clamp level (80 mg/dl). This problem was considered  to indicate the necessity of the improvement for measuring the M value  in patients with severe GT (eg increasing the amount of insulin infusion,  stopping intravenous drip infusion earlier than 09:00 h, etc).</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>16221</offset><text>There are many factors that influence BG or the GT. Stress hormones and  thyroid-related hormones are well known to be included in those factors, and  they are also used as the drugs. In the present study in which the AP strictly  controlled BG, however, those hormones did not significantly influence the  glucose tolerance. This is determined from the results that there were no  significant correlations between the M value and the blood  concentration of these hormones (Table 5), and that there  were no significant differences in the M values between the patients  who were administered these hormones and those who were not. We consider that  sepsis induced by some other factors other than these hormones impaired the  glucose tolerance.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>16967</offset><text>The relationship between GT including fat metabolism and hypercoagulability,  indicated by the increased levels of PAI-1 or tPA-PAI-1 complex, has been well  investigated in the patients with NIDDM, with hypertension, with coronary artery disease,  and in the normal human subjects or the general population. In these studies, PAI-1 or tPA-PAI  complex was closely related with, and thought to be caused by,  hyperinsulinemia, hyperglycemia, insulin resistance, hypertriglyceridemia,  hypercholesterolemia, and increased level of high density lipoprotein  cholesterol. In vitro studies using endothelial cells, hepatoma cells,  or vascular smooth muscle cells showed that PAI-1 was produced by glucose,  insulin, free fatty acid, cholesterol, very low density lipoprotein,  glucocorticoids, and hyperosmolarity. In our study performed under strict blood  glucose control by means of AP, however, the glucose intolerance was not a  significant factor influencing MODS and coagulopathy, considering from the  results that there were no significant correlations between the M  value and the MOF score, parameters related with coagulation and fibrinolysis  (Table 6). In addition, under this strict blood glucose  control, BG, blood insulin and fat levels did not significantly influence the  coagulopathy, because there were no significant correlations between parameters  related with coagulation and fibrinolysis and daily mean BG, blood insulin  concentration, and serum fat (triglyceride, total cholesterol, free fatty acid)  levels (data not shown). These results are considered to indicate that the  influence of the GT and the factors related with the glucose tolerance (eg BG,  blood insulin and fat levels) to coagulopathy could be excluded by the strict  blood glucose control using AP.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>18761</offset><text>Relationships between coagulopathy and chronic organ dysfunctions have been  well investigated. The hypercoagulable state or decreased fibrinolytic activity  in NIDDM patients, shown by increased levels of PAI-1, fibrinogen, factor VII,  von Willebrand factor, and tPA, are considered to be risk factors of  cardiovascular diseases. Increased PAI-1 level is especially thought to be a  causative factor of atherosclerosis. In patients other than those with NIDDM,  including those with insulin-dependent diabetes mellitus, history of myocardial infarction, and  hypertension, hypercoagulable states with increased PAI-1 level are  also considered to be one of the risk factors of coronary atherosclerosis or  hypertension. Increased PAI-1 level seems to be the cause of, and not only the  result of, cardiovascular diseases or atherosclerosis, because it was shown in  an animal study that increased expression of PAI-1 in the arterial wall  preceded atherosclerosis.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>19729</offset><text>Relationships between hypercoagulable state and sepsis or septic MODS have  been investigated in recent years. The  hypercoagulable state, shown by increased levels of PAI-1, TAT, and prothrombin fragment 1 + 2, and by  decreased levels of AT-III [ ,], factor VII, and protein C, were reported in these studies to be closely related to septic  MODS. As mentioned in the Introduction, however, metabolic factors including  glucose and fat that are considered to influence those parameters related with  coagulopathy are not taken into consideration in those investigations. In our  study, performed with strict blood glucose control by AP, the MOF score (mMOF  score) was positively correlated with the DIC score, TAT, and tPA-PAI-1  complex, and was negatively correlated with PLT (Tables 7  and 8; Fig. 2). The tPA-PAI-1  complex, which is reported to positively correlate with tPA, is considered to be a parameter of hypercoagulability and decreased  fibrinolysis, and to be closely related with thrombotic diseases. The tPA-PAI-1 complex was in  fact also positively related with TAT (Table 10) in this  study, which is the parameter of hypercoagulability. On the contrary, there  were no significant correlations between the MOF score (mMOF score) and  parameters related with fibrinolysis (α2 plasmin  inhibitor-plasmin complex, fibrin and fibrinogen degradation products,  D-dimer). Judging from the aforementioned results in the present study,  hypercoagulability and decreased fibrinolysis, indicated by the increase of the  tPA-PAI-1 complex and TAT, were considered to be closely related with MODS in  acutely ill septic patients. The tPA-PAI-1 complex, which is not used for  calculating the MOF score and the DIC score, also seemed to be a useful and  sensitive marker of MODS.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>21523</offset><text>Moreover, a hypercoagulable state indicated by the elevated tPA-PAI-1 level  may be one of the risk factors and predictive markers of MODS. This follows  from studies reporting that the hypercoagulable state preceded MODS, in which  significant changes of the parameters related with hypercoagulability were  found at the onset of sepsis. We also found that  changes of the tPA-PAI-1 complex preceded those of organ dysfunctions in some  cases (data not shown). These findings suggest that the hypercoagulable state  disturbs microcirculation and leads to MODS.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>22085</offset><text>There were close correlations between MOF score (mMOF score) and TAT and  tPA-PAI-1 complex, but no significant correlations between MOF score (mMOF  score) and PAI-1, AT-III, and protein C in our study. The reasons for this are  not clear, but may be related to the conditions in which our investigation was  performed under strict blood glucose control by means of AP, related to the  limited number of the patients in our study, or related to the origin of the  parameters. PAI-1 is synthesized not only by the endothelium, but also by the  liver, vascular smooth muscle cells, and platelets.  AT-III is synthesized by the liver and endothelium, and protein C by the liver.  On the contrary, the tPA-PAI-1 complex is considered to be synthesized mainly  by the activated endothelium, because the tPA-PAI-1 complex is the indicator of  tPA, as already mentioned, and tPA is synthesized by the endothelium activated  with thrombin, cytokines (eg tumor necrosis factor, interleukin-2), endotoxin,  endothelin, catecholamine, histamine, and activated protein C. A positive  correlation between MOF score (mMOF score) and tPA-PAI-1 complex therefore  suggests not only a close relationship between organ dysfunction and  hyper-coagulability, but also an intimate relationship between organ  dysfunction and endothelial cell activation.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>23419</offset><text>Endothelial cell injury was closely related with MODS and coagulopathy  characterized by hypercoagulability with decreased fibrinolysis, judging from  the results that TM was closely correlated with MOF score, DIC score, tPA-PAI-1  complex, TAT, and PLT (Table 9; Figs  3 and 4). These results are consistent with the  other reports that endothelial cell activation or injury, which are caused by  endotoxin, cytokines, complement, and neutrophils [ , ], causes a hypercoagulable state or DIC, which leads to MODS. TM is usually  considered to be one of the markers of endothelial cell injury. However, TM  also seemed to be a marker of endothelial cell activation in septic patients,  because there was positive correlation between TM and tPA-PAI-1 complex (Table  9), which was considered to be one of the parameters of  endothelial cell activation as mentioned earlier.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>24292</offset><text>Conclusion</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>24303</offset><text>We investigated acutely ill septic patients with glucose intolerance in  which BG was strictly controlled and the glucose tolerance was measured by the  glucose clamp method by means of AP, and obtained the following conclusions.  The GT did not significantly relate with blood stress related hormone levels,  coagulopathy and MODS under strict blood glucose control. Coagulopathy  characterized by hypercoagulability with decreased fibrinolysis was closely  related with MODS and endothelial cell injury. Among the parameters related  with coagulation and fibrinolysis, the tPA-PAI-1 complex, considered to  originate from activated endothelium, seemed to be a sensitive parameter of  MODS and endothelial cell injury, and might be one of the predictive and risk  factors of MODS. Finally, the treatment for reducing hypercoagulability and  endothelial cell activation/endothelial cell injury was thought to be justified  as one of the therapies for acutely ill septic patients.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>25283</offset><text>Further investigation will, however, be necessary for clarifying these  conclusions because the number of the patients we investigated was limited.</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">title_1</infon><offset>25431</offset><text>Abbreviations</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>25445</offset><text>AP = artificial pancreas; AT-III = antithrombin III; BG = blood glucose  level; DIC = disseminated intravascular coagulation; ECA = endothelial cell  activation; ECI = endothelial cell injury; GT = glucose tolerance; MODS =  multiple organ dysfunction syndrome; mMOF = modified multiple organ failure;  NIDDM = noninsulin-dependent diabetes mellitus; PAI-1 = plasminogen activator  inhibitor-1; PLT = platelet count; PT = prothrombin time; SRH = stress related  hormone; TAT = thrombin-antithrombin III complex; TM = thrombomodulin; tPA =  tissue plasminogen activator; T3 = triiodothyronine; T4 =  thyroxine.</text></passage><passage><infon key="fpage">945</infon><infon key="lpage">949</infon><infon key="name_0">surname:Potter van Loon;given-names:BJ</infon><infon key="name_1">surname:Kluft;given-names:C</infon><infon key="name_2">surname:Radder;given-names:JK</infon><infon key="name_3">surname:Blankenstein;given-names:MA</infon><infon key="name_4">surname:Meinders;given-names:AE</infon><infon key="pub-id_pmid">8345817</infon><infon key="section_type">REF</infon><infon key="source">Metabolism</infon><infon key="type">ref</infon><infon key="volume">42</infon><infon key="year">1993</infon><offset>26055</offset><text>The cardiovascular risk factor plasminogen activator inhibitor type 1  is related to insulin resistance.</text></passage><passage><infon key="fpage">457</infon><infon key="lpage">462</infon><infon key="name_0">surname:Vague;given-names:IJ</infon><infon key="name_1">surname:Alessi;given-names:MC</infon><infon key="name_2">surname:Vague;given-names:P</infon><infon key="pub-id_pmid">1916049</infon><infon key="section_type">REF</infon><infon key="source">Diabetologia</infon><infon key="type">ref</infon><infon key="volume">34</infon><infon key="year">1991</infon><offset>26160</offset><text>Increased plasma plasminogen activator inhibitor-1 levels. A possible  link between insulin resistance and atherothrombosis.</text></passage><passage><infon key="fpage">273</infon><infon key="lpage">278</infon><infon key="name_0">surname:Landin;given-names:K</infon><infon key="name_1">surname:Tengborn;given-names:L</infon><infon key="name_2">surname:Smith;given-names:U</infon><infon key="section_type">REF</infon><infon key="source">J Int Med</infon><infon key="type">ref</infon><infon key="volume">227</infon><infon key="year">1990</infon><offset>26285</offset><text>Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in  hypertension are related to metabolic risk factors for cardiovascular  diseases.</text></passage><passage><infon key="fpage">1044</infon><infon key="lpage">1048</infon><infon key="name_0">surname:Landin;given-names:K</infon><infon key="name_1">surname:Stigendal;given-names:L</infon><infon key="name_2">surname:Eriksson;given-names:E</infon><infon key="name_3">surname:Krotkiewski;given-names:M</infon><infon key="name_4">surname:Risberg;given-names:B</infon><infon key="name_5">surname:Tengborn;given-names:L</infon><infon key="name_6">surname:Smith;given-names:U</infon><infon key="pub-id_pmid">2215252</infon><infon key="section_type">REF</infon><infon key="source">Metabolism</infon><infon key="type">ref</infon><infon key="volume">39</infon><infon key="year">1990</infon><offset>26434</offset><text>Abdominal obesity is associated with an impaired fibrinolytic  activity and elevated plasminogen activator inhibitor-1.</text></passage><passage><infon key="fpage">371</infon><infon key="lpage">380</infon><infon key="name_0">surname:Juhan-Vague;given-names:I</infon><infon key="name_1">surname:Alessi;given-names:MC</infon><infon key="name_2">surname:Vague;given-names:P</infon><infon key="pub-id_pmid">8862693</infon><infon key="section_type">REF</infon><infon key="source">Ann Med</infon><infon key="type">ref</infon><infon key="volume">28</infon><infon key="year">1996</infon><offset>26554</offset><text>Thrombogenic and fibrinolytic factors and cardiovascular risk in  non-insulin-dependent diabetes mellitus.</text></passage><passage><infon key="fpage">141</infon><infon key="lpage">147</infon><infon key="name_0">surname:Schneider;given-names:DJ</infon><infon key="name_1">surname:Absher;given-names:PM</infon><infon key="name_2">surname:Neimane;given-names:D</infon><infon key="name_3">surname:Russell;given-names:JC</infon><infon key="name_4">surname:Sobel;given-names:BE</infon><infon key="pub-id_pmid">9498646</infon><infon key="section_type">REF</infon><infon key="source">Diabetologia</infon><infon key="type">ref</infon><infon key="volume">41</infon><infon key="year">1998</infon><offset>26661</offset><text>Fibrinolysis and atherogenesis in the JCR: LA-cp rat in relation to  insulin and triglyceride concentrations in blood.</text></passage><passage><infon key="fpage">631</infon><infon key="lpage">636</infon><infon key="name_0">surname:Leithauser;given-names:B</infon><infon key="name_1">surname:Matthias;given-names:FR</infon><infon key="name_2">surname:Nicolai;given-names:U</infon><infon key="name_3">surname:Voss;given-names:R</infon><infon key="pub-id_pmid">8844226</infon><infon key="section_type">REF</infon><infon key="source">Intensive Care Med</infon><infon key="type">ref</infon><infon key="volume">22</infon><infon key="year">1996</infon><offset>26780</offset><text>Hemostatic abnormalities and the severity of illness in patients at  the onset of clinically defined sepsis. Possible indication of the degree of  endothelial cell activation</text></passage><passage><infon key="fpage">829</infon><infon key="lpage">832</infon><infon key="name_0">surname:Asakura;given-names:H</infon><infon key="name_1">surname:Jokaji;given-names:H</infon><infon key="name_2">surname:Saito;given-names:M</infon><infon key="name_3">surname:Uotani;given-names:C</infon><infon key="name_4">surname:Kumabashiri;given-names:I</infon><infon key="name_5">surname:Morishita;given-names:E</infon><infon key="name_6">surname:Yamazaki;given-names:M</infon><infon key="name_7">surname:Aoshima;given-names:K</infon><infon key="name_8">surname:Matsuda;given-names:T</infon><infon key="section_type">REF</infon><infon key="source">Blood Coag Fibrinol</infon><infon key="type">ref</infon><infon key="volume">5</infon><infon key="year">1994</infon><offset>26955</offset><text>Study of the balance between coagulation and fibrinolysis in  disseminated intravascular coagulation using molecular markers.</text></passage><passage><infon key="fpage">328</infon><infon key="lpage">334</infon><infon key="name_0">surname:Inthorn;given-names:D</infon><infon key="name_1">surname:Hoffmann;given-names:JN</infon><infon key="name_2">surname:Hartl;given-names:WH</infon><infon key="name_3">surname:Muhlbayer;given-names:D</infon><infon key="name_4">surname:Jochum;given-names:M</infon><infon key="pub-id_pmid">9361342</infon><infon key="section_type">REF</infon><infon key="source">Shock</infon><infon key="type">ref</infon><infon key="volume">8</infon><infon key="year">1997</infon><offset>27081</offset><text>Antithrombin III supplementation in severe sepsis: beneficial effects  on organ dysfunction.</text></passage><passage><infon key="fpage">223</infon><infon key="lpage">228</infon><infon key="name_0">surname:Kidokoro;given-names:A</infon><infon key="name_1">surname:Iba;given-names:T</infon><infon key="name_2">surname:Fukunaga;given-names:M</infon><infon key="name_3">surname:Yagi;given-names:Y</infon><infon key="pub-id_pmid">8696988</infon><infon key="section_type">REF</infon><infon key="source">Shock</infon><infon key="type">ref</infon><infon key="volume">5</infon><infon key="year">1996</infon><offset>27174</offset><text>Alterations in coagulation and fibrinolysis during sepsis.</text></passage><passage><infon key="fpage">881</infon><infon key="lpage">886</infon><infon key="name_0">surname:Mesters;given-names:RM</infon><infon key="name_1">surname:Mannucci;given-names:PM</infon><infon key="name_2">surname:Coppola;given-names:R</infon><infon key="name_3">surname:Keller;given-names:T</infon><infon key="name_4">surname:Ostermann;given-names:H</infon><infon key="name_5">surname:Kienast;given-names:J</infon><infon key="pub-id_pmid">8704245</infon><infon key="section_type">REF</infon><infon key="source">Blood</infon><infon key="type">ref</infon><infon key="volume">88</infon><infon key="year">1996</infon><offset>27233</offset><text>Factor VIIa a and antithrombin III activity during severe sepsis and  septic shock in neutropenic patients.</text></passage><passage><infon key="fpage">816</infon><infon key="lpage">823</infon><infon key="name_0">surname:Fourrier;given-names:F</infon><infon key="name_1">surname:Chopin;given-names:C</infon><infon key="name_2">surname:Goudemand;given-names:J</infon><infon key="name_3">surname:Hendrycx;given-names:S</infon><infon key="name_4">surname:Caron;given-names:C</infon><infon key="name_5">surname:Rime;given-names:A</infon><infon key="name_6">surname:Marey;given-names:A</infon><infon key="name_7">surname:Lestavel;given-names:P</infon><infon key="pub-id_pmid">1531791</infon><infon key="section_type">REF</infon><infon key="source">Chest</infon><infon key="type">ref</infon><infon key="volume">101</infon><infon key="year">1992</infon><offset>27341</offset><text>Septic shock, multiple organ failure, and disseminated intravascular  coagulation. Compared paterns of antithrombin III, protein C, and protein S  deficiencies.</text></passage><passage><infon key="fpage">224</infon><infon key="lpage">228</infon><infon key="name_0">surname:Gando;given-names:S</infon><infon key="name_1">surname:Kameue;given-names:T</infon><infon key="name_2">surname:Nanzaki;given-names:S</infon><infon key="name_3">surname:Nakanishi;given-names:Y</infon><infon key="pub-id_pmid">8815564</infon><infon key="section_type">REF</infon><infon key="source">Thromb Haemost</infon><infon key="type">ref</infon><infon key="volume">75</infon><infon key="year">1996</infon><offset>27502</offset><text>Disseminated intravascular coagulation in a frequent complication of  systemic inflammatory response syndrome.</text></passage><passage><infon key="fpage">660</infon><infon key="lpage">664</infon><infon key="name_0">surname:Gando;given-names:S</infon><infon key="name_1">surname:Nakanishi;given-names:Y</infon><infon key="name_2">surname:Kameue;given-names:T</infon><infon key="name_3">surname:Nanzaki;given-names:S</infon><infon key="pub-id_pmid">7473950</infon><infon key="section_type">REF</infon><infon key="source">J Trauma</infon><infon key="type">ref</infon><infon key="volume">39</infon><infon key="year">1995</infon><offset>27613</offset><text>Soluble thrombomodulin increases in patients with disseminated  intravascular coagulation and in those with multiple organ dysfunction syndrome  after trauma: role of neutrophil elastase.</text></passage><passage><infon key="fpage">819</infon><infon key="lpage">827</infon><infon key="name_0">surname:Nachman;given-names:RL</infon><infon key="name_1">surname:Silverstein;given-names:R</infon><infon key="pub-id_pmid">8379603</infon><infon key="section_type">REF</infon><infon key="source">Ann Intern Med</infon><infon key="type">ref</infon><infon key="volume">119</infon><infon key="year">1993</infon><offset>27801</offset><text>Hypercoagulable states.</text></passage><passage><infon key="fpage">277</infon><infon key="lpage">288</infon><infon key="name_0">surname:Endo;given-names:S</infon><infon key="name_1">surname:Inada;given-names:K</infon><infon key="name_2">surname:Nakae;given-names:H</infon><infon key="name_3">surname:Takakuwa;given-names:T</infon><infon key="name_4">surname:Kasai;given-names:T</infon><infon key="name_5">surname:Yamada;given-names:Y</infon><infon key="name_6">surname:Suzuki;given-names:T</infon><infon key="name_7">surname:Taniguchi;given-names:S</infon><infon key="name_8">surname:Yoshida;given-names:M</infon><infon key="pub-id_pmid">8747795</infon><infon key="section_type">REF</infon><infon key="source">Res Commun Mol Pathol Pharmacol</infon><infon key="type">ref</infon><infon key="volume">90</infon><infon key="year">1995</infon><offset>27825</offset><text>Blood levels of endothelin-1 and thrombomodulin in patients with  disseminated intravascular coagulation and sepsis.</text></passage><passage><infon key="fpage">629</infon><infon key="lpage">651</infon><infon key="name_0">surname:Pearson;given-names:JD</infon><infon key="pub-id_pmid">8025346</infon><infon key="section_type">REF</infon><infon key="source">Baillieres Clin Haematol</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">1993</infon><offset>27942</offset><text>The control of production and release of haemostatic factors in the  endothelial cell.</text></passage><passage><infon key="fpage">183</infon><infon key="lpage">190</infon><infon key="name_0">surname:Dawson;given-names:S</infon><infon key="name_1">surname:Hamsten;given-names:A</infon><infon key="name_2">surname:Wiman;given-names:B</infon><infon key="name_3">surname:Henney;given-names:A</infon><infon key="name_4">surname:Humphries;given-names:S</infon><infon key="pub-id_pmid">1670989</infon><infon key="section_type">REF</infon><infon key="source">Arterioscler Thromb</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">1991</infon><offset>28029</offset><text>Genetic variation at the plasminogen activator inhibitor-1 locus is  associated with altered levels of plasminogen activator inhibitor-1  activity.</text></passage><passage><infon key="fpage">1822</infon><infon key="lpage">1828</infon><infon key="name_0">surname:Nordt;given-names:TK</infon><infon key="name_1">surname:Klassen;given-names:KJ</infon><infon key="name_2">surname:Schneider;given-names:DJ</infon><infon key="name_3">surname:Sobel;given-names:BE</infon><infon key="pub-id_pmid">8241103</infon><infon key="section_type">REF</infon><infon key="source">Arterioscler Thromb</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">1993</infon><offset>28177</offset><text>Augumentation of synthesis of plasminogen activator inhibitor type-1  in arterial endothelial cells by glucose and its implications for local  fibrinolysis.</text></passage><passage><infon key="fpage">1009</infon><infon key="lpage">1015</infon><infon key="name_0">surname:Maiello;given-names:M</infon><infon key="name_1">surname:Boeri;given-names:D</infon><infon key="name_2">surname:Podesta;given-names:F</infon><infon key="name_3">surname:Cagliero;given-names:E</infon><infon key="name_4">surname:Vichi;given-names:M</infon><infon key="name_5">surname:Odetti;given-names:P</infon><infon key="name_6">surname:Adezati;given-names:L</infon><infon key="name_7">surname:Lorenzi;given-names:M</infon><infon key="pub-id_pmid">1628760</infon><infon key="section_type">REF</infon><infon key="source">Diabetes</infon><infon key="type">ref</infon><infon key="volume">41</infon><infon key="year">1992</infon><offset>28334</offset><text>Increased expression of tissue plasminogen activator and its  inhibitor and reduced fibrinolytic potential of human endothelial cells  cultured in elevated glucose.</text></passage><passage><infon key="fpage">1425</infon><infon key="lpage">1431</infon><infon key="name_0">surname:Pandolfi;given-names:A</infon><infon key="name_1">surname:Iacoviello;given-names:L</infon><infon key="name_2">surname:Capani;given-names:F</infon><infon key="name_3">surname:Vitacolonna;given-names:E</infon><infon key="name_4">surname:Donati;given-names:MB</infon><infon key="name_5">surname:Consoli;given-names:A</infon><infon key="pub-id_pmid">8960822</infon><infon key="section_type">REF</infon><infon key="source">Diabetologia</infon><infon key="type">ref</infon><infon key="volume">39</infon><infon key="year">1996</infon><offset>28499</offset><text>Glucose and insulin independently reduce the fibrinolytic potential  of human vascular smooth muscle cells in culture.</text></passage><passage><infon key="fpage">813</infon><infon key="lpage">817</infon><infon key="name_0">surname:Schneider;given-names:DJ</infon><infon key="name_1">surname:Sobel;given-names:BE</infon><infon key="section_type">REF</infon><infon key="source">Coronary Artery Dis</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">1996</infon><offset>28618</offset><text>Synergistic augumentation of expression of plasminogen activator  inhibitor type-1 induced by insulin, very-low-density lipoproteins, and fatty  acids.</text></passage><passage><infon key="fpage">8225</infon><infon key="lpage">8231</infon><infon key="name_0">surname:Chen;given-names:YQ</infon><infon key="name_1">surname:Su;given-names:M</infon><infon key="name_2">surname:Walia;given-names:RR</infon><infon key="name_3">surname:Hao;given-names:Q</infon><infon key="name_4">surname:Covington;given-names:JW</infon><infon key="name_5">surname:Vaughan;given-names:DE</infon><infon key="pub-id_pmid">9525928</infon><infon key="section_type">REF</infon><infon key="source">J Biol Chem</infon><infon key="type">ref</infon><infon key="volume">273</infon><infon key="year">1998</infon><offset>28770</offset><text>Sp1 sites mediate activation of the plasminogen activator inhibitor-1  promotor by glucose in vascular smooth muscle cells.</text></passage><passage><infon key="fpage">1644</infon><infon key="lpage">1655</infon><infon key="pub-id_pmid">1303622</infon><infon key="section_type">REF</infon><infon key="source">Chest</infon><infon key="type">ref</infon><infon key="volume">101</infon><infon key="year">1992</infon><offset>28894</offset><text>Members of the American College of Chest Physicians/Society of  Critical Care Medicine Consensus Conference Committee.</text></passage><passage><infon key="fpage">103</infon><infon key="lpage">144</infon><infon key="name_0">surname:Haraguchi;given-names:Y</infon><infon key="section_type">REF</infon><infon key="source">J Jpn Assoc Crit Care Med</infon><infon key="type">ref</infon><infon key="volume">4</infon><infon key="year">1990</infon><offset>29013</offset><text>General discussion. Multiple organ failure IV: DIC bleeding from  digestive tract.</text></passage><passage><infon key="fpage">E214</infon><infon key="lpage">E223</infon><infon key="name_0">surname:DeFronzo;given-names:RA</infon><infon key="name_1">surname:Tobin;given-names:JD</infon><infon key="name_2">surname:Andres;given-names:AR</infon><infon key="pub-id_pmid">382871</infon><infon key="section_type">REF</infon><infon key="source">Am J Physiol</infon><infon key="type">ref</infon><infon key="volume">237</infon><infon key="year">1979</infon><offset>29096</offset><text>Glucose clamp technique: a method for quantifying insulin secretion  and resistance.</text></passage><passage><infon key="fpage">86</infon><infon key="lpage">95</infon><infon key="name_0">surname:Shmueli;given-names:E</infon><infon key="name_1">surname:Walker;given-names:M</infon><infon key="name_2">surname:Alberti;given-names:G</infon><infon key="pub-id_pmid">8100799</infon><infon key="section_type">REF</infon><infon key="source">Hepatology</infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="year">1993</infon><offset>29181</offset><text>Normal splanchnic but impaired peripheral insulin-stimulated glucose  uptake in cirrhosis.</text></passage><passage><infon key="fpage">37</infon><infon key="lpage">41</infon><infon key="name_0">surname:Aoki;given-names:N</infon><infon key="name_1">surname:Hasegawa;given-names:H</infon><infon key="section_type">REF</infon><infon key="source">Annual Report of the Research Committee on Coagulation disorders 
Edited by Aoki N Tokyo: Ministry of Health and Welfare of Japan,</infon><infon key="type">ref</infon><infon key="year">1988</infon><offset>29272</offset><text>On the revised form of the comfirmatory tests in diagnostic criteria  for DIC.</text></passage><passage><infon key="fpage">363</infon><infon key="lpage">370</infon><infon key="name_0">surname:Haffner;given-names:SM</infon><infon key="pub-id_pmid">8862692</infon><infon key="section_type">REF</infon><infon key="source">Ann Med</infon><infon key="type">ref</infon><infon key="volume">28</infon><infon key="year">1996</infon><offset>29351</offset><text>Cardiovascular risk factors and the prediabetic syndrome.</text></passage><passage><infon key="fpage">1074</infon><infon key="lpage">1079</infon><infon key="name_0">surname:Lormeau;given-names:B</infon><infon key="name_1">surname:Aurousseau;given-names:MH</infon><infon key="name_2">surname:Valensi;given-names:P</infon><infon key="name_3">surname:Paries;given-names:J</infon><infon key="name_4">surname:Attali;given-names:JR</infon><infon key="pub-id_pmid">9284899</infon><infon key="section_type">REF</infon><infon key="source">Metabolism</infon><infon key="type">ref</infon><infon key="volume">46</infon><infon key="year">1997</infon><offset>29409</offset><text>Hyper-insulinemia and hypofibrinolysis: effects of short term  optimized glycemic control with continuous insulin infusion in type II diabetic  patients.</text></passage><passage><infon key="fpage">692</infon><infon key="lpage">697</infon><infon key="name_0">surname:Lemne;given-names:C</infon><infon key="name_1">surname:De Faire;given-names:U</infon><infon key="pub-id_pmid">8872066</infon><infon key="section_type">REF</infon><infon key="source">Eur J Clin Invest</infon><infon key="type">ref</infon><infon key="volume">26</infon><infon key="year">1996</infon><offset>29563</offset><text>Elevation of plasminogen activator inhibitor 1 in borderline  hypertension is linked to concomitant metabolic disturbances.</text></passage><passage><infon key="fpage">484</infon><infon key="lpage">490</infon><infon key="name_0">surname:Jeng;given-names:JR</infon><infon key="name_1">surname:Sheu;given-names:WH</infon><infon key="name_2">surname:Jeng;given-names:CY</infon><infon key="name_3">surname:Huang;given-names:SH</infon><infon key="name_4">surname:Shieh;given-names:SM</infon><infon key="pub-id_pmid">8735180</infon><infon key="section_type">REF</infon><infon key="source">Am J Hypertens</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">1996</infon><offset>29687</offset><text>Impaired fibrinolysis and insulin resistance in patients with  hypertension.</text></passage><passage><infon key="fpage">659</infon><infon key="lpage">666</infon><infon key="name_0">surname:Cigolini;given-names:M</infon><infon key="name_1">surname:Targher;given-names:G</infon><infon key="name_2">surname:Seidell;given-names:JC</infon><infon key="name_3">surname:Tonoli;given-names:M</infon><infon key="name_4">surname:Schiavon;given-names:R</infon><infon key="name_5">surname:Agostino;given-names:G</infon><infon key="name_6">surname:De Sandre;given-names:G</infon><infon key="pub-id_pmid">7594424</infon><infon key="section_type">REF</infon><infon key="source">J Hypertens</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">1995</infon><offset>29764</offset><text>Relationships of blood pressure to fibrinolysis: influence of  anthropometry, metabolic profile and behavioural variables.</text></passage><passage><infon key="fpage">321</infon><infon key="lpage">327</infon><infon key="name_0">surname:Tomiyama;given-names:H</infon><infon key="name_1">surname:Kimura;given-names:Y</infon><infon key="name_2">surname:Mitsuhashi;given-names:H</infon><infon key="name_3">surname:Kinouchi;given-names:T</infon><infon key="name_4">surname:Yoshida;given-names:H</infon><infon key="name_5">surname:Kushiro;given-names:T</infon><infon key="name_6">surname:Doba;given-names:N</infon><infon key="pub-id_pmid">9453323</infon><infon key="section_type">REF</infon><infon key="source">Hypertension</infon><infon key="type">ref</infon><infon key="volume">31</infon><infon key="year">1998</infon><offset>29887</offset><text>Relationship between endothelial function and fibrinolysis in early  hypertension.</text></passage><passage><infon key="fpage">568</infon><infon key="lpage">575</infon><infon key="name_0">surname:Bavenholm;given-names:P</infon><infon key="name_1">surname:Proudler;given-names:A</infon><infon key="name_2">surname:Silveira;given-names:A</infon><infon key="name_3">surname:Crook;given-names:D</infon><infon key="name_4">surname:Blomback;given-names:M</infon><infon key="name_5">surname:de Faire;given-names:U</infon><infon key="name_6">surname:Hamsten;given-names:A</infon><infon key="pub-id_pmid">7495060</infon><infon key="section_type">REF</infon><infon key="source">Thromb Haemost</infon><infon key="type">ref</infon><infon key="volume">73</infon><infon key="year">1995</infon><offset>29970</offset><text>Relationships of insulin and intact and split proinsulin to  haemostatic function in young men with and without coronary artery disease.</text></passage><passage><infon key="fpage">290</infon><infon key="lpage">293</infon><infon key="name_0">surname:Calles-Escandon;given-names:J</infon><infon key="name_1">surname:Mirza;given-names:SA</infon><infon key="name_2">surname:Sobel;given-names:BE</infon><infon key="name_3">surname:Schneider;given-names:DJ</infon><infon key="pub-id_pmid">9519730</infon><infon key="section_type">REF</infon><infon key="source">Diabetes</infon><infon key="type">ref</infon><infon key="volume">47</infon><infon key="year">1998</infon><offset>30107</offset><text>Induction of hyperinsulinemia combined with hyperglycemia and  hyper-triglyceridemia increases plasminogen activator inhibitor 1 in blood in  normal human subjects.</text></passage><passage><infon key="fpage">291</infon><infon key="lpage">299</infon><infon key="name_0">surname:Lindahl;given-names:B</infon><infon key="name_1">surname:Asplund;given-names:K</infon><infon key="name_2">surname:Eliasson;given-names:M</infon><infon key="name_3">surname:Evrin;given-names:P-E</infon><infon key="pub-id_pmid">9119554</infon><infon key="section_type">REF</infon><infon key="source">Int J Epidemiol</infon><infon key="type">ref</infon><infon key="volume">25</infon><infon key="year">1996</infon><offset>30272</offset><text>Insulin resistance syndrome and fibrinolytic activity: the northern  Sweden MONICA study.</text></passage><passage><infon key="fpage">2213</infon><infon key="lpage">2221</infon><infon key="name_0">surname:Sobel;given-names:BE</infon><infon key="name_1">surname:Woodcock-Mitchell;given-names:J</infon><infon key="name_2">surname:Schneider;given-names:DJ</infon><infon key="name_3">surname:Holt;given-names:RE</infon><infon key="name_4">surname:Marutsuka;given-names:K</infon><infon key="name_5">surname:Gold;given-names:H</infon><infon key="pub-id_pmid">9631870</infon><infon key="section_type">REF</infon><infon key="source">Circulation</infon><infon key="type">ref</infon><infon key="volume">97</infon><infon key="year">1998</infon><offset>30362</offset><text>Increased plasminogen activator inhibitor type 1 in coronary artery  atherectomy specimens from type 2 diabetic compared with nondiabetic patients:  a potential factor predisposing to thrombosis and its persistence.</text></passage><passage><infon key="fpage">85</infon><infon key="lpage">92</infon><infon key="name_0">surname:Avellone;given-names:G</infon><infon key="name_1">surname:Di Garbo;given-names:V</infon><infon key="name_2">surname:Cordova;given-names:R</infon><infon key="name_3">surname:Rotolo;given-names:G</infon><infon key="name_4">surname:Abruzzese;given-names:G</infon><infon key="name_5">surname:Raneli;given-names:G</infon><infon key="name_6">surname:De Simone;given-names:R</infon><infon key="name_7">surname:Bompiani;given-names:GD</infon><infon key="pub-id_pmid">7648783</infon><infon key="section_type">REF</infon><infon key="source">Diabetes Res</infon><infon key="type">ref</infon><infon key="volume">25</infon><infon key="year">1994</infon><offset>30578</offset><text>Blood coagulation and fibrinolysis in obese NIDDM patients.</text></passage><passage><infon key="fpage">643</infon><infon key="lpage">654</infon><infon key="name_0">surname:Carmassi;given-names:F</infon><infon key="name_1">surname:Morale;given-names:M</infon><infon key="name_2">surname:Puccetti;given-names:R</infon><infon key="name_3">surname:De Negri;given-names:F</infon><infon key="name_4">surname:Monzani;given-names:F</infon><infon key="name_5">surname:Navalesi;given-names:R</infon><infon key="name_6">surname:Mariani;given-names:G</infon><infon key="pub-id_pmid">1440530</infon><infon key="section_type">REF</infon><infon key="source">Thromb Res</infon><infon key="type">ref</infon><infon key="volume">67</infon><infon key="year">1992</infon><offset>30638</offset><text>Coagulation and fibrinolytic system impairment in insulin dependent  diabetes mellitus.</text></passage><passage><infon key="fpage">402</infon><infon key="lpage">410</infon><infon key="name_0">surname:Bavenholm;given-names:P</infon><infon key="name_1">surname:de Faire;given-names:U</infon><infon key="name_2">surname:Landou;given-names:C</infon><infon key="name_3">surname:Efendic;given-names:S</infon><infon key="name_4">surname:Nilsson;given-names:J</infon><infon key="name_5">surname:Wiman;given-names:B</infon><infon key="name_6">surname:Hamsten;given-names:A</infon><infon key="pub-id_pmid">9568444</infon><infon key="section_type">REF</infon><infon key="source">Eur Heart J</infon><infon key="type">ref</infon><infon key="volume">19</infon><infon key="year">1998</infon><offset>30726</offset><text>Progression of coronary artery disease in young male post-infarction  patients is linked to disturbances of carbohydrate and lipoprotein matabolism  and impaired fibrinolytic function.</text></passage><passage><infon key="fpage">475</infon><infon key="lpage">784</infon><infon key="name_0">surname:Nordenhem;given-names:A</infon><infon key="name_1">surname:Wiman;given-names:B</infon><infon key="pub-id_pmid">9832339</infon><infon key="section_type">REF</infon><infon key="source">Scand J Clin Lab Invest</infon><infon key="type">ref</infon><infon key="volume">58</infon><infon key="year">1998</infon><offset>30911</offset><text>Tissue plasminogen activator (tPA) antigen in plasma: correlation  with different tPA/inhibitor complexes.</text></passage><passage><infon key="fpage">351</infon><infon key="lpage">358</infon><infon key="name_0">surname:Yamauchi;given-names:K</infon><infon key="name_1">surname:Suzuki;given-names:T</infon><infon key="name_2">surname:Furumichi;given-names:T</infon><infon key="name_3">surname:Saito;given-names:H</infon><infon key="pub-id_pmid">1522691</infon><infon key="section_type">REF</infon><infon key="source">Jpn Heart J</infon><infon key="type">ref</infon><infon key="volume">33</infon><infon key="year">1992</infon><offset>31018</offset><text>Plasma tPA/PAI-1 complex and blood coagulability in patients with  coronary artery disease.</text></passage><passage><infon key="fpage">389</infon><infon key="lpage">393</infon><infon key="name_0">surname:Niwano;given-names:H</infon><infon key="name_1">surname:Takahashi;given-names:H</infon><infon key="name_2">surname:Tatewaki;given-names:W</infon><infon key="name_3">surname:Wada;given-names:K</infon><infon key="name_4">surname:Seki;given-names:Y</infon><infon key="name_5">surname:Shibata;given-names:A</infon><infon key="section_type">REF</infon><infon key="source">BloodCoag Fibrinol</infon><infon key="type">ref</infon><infon key="volume">3</infon><infon key="year">1992</infon><offset>31110</offset><text>Behaviour of tissue plasminogen activator, plasminogen activator  inhibitor 1 and their complex in various disease states.</text></passage><passage><infon key="fpage">176</infon><infon key="lpage">183</infon><infon key="name_0">surname:Asakura;given-names:H</infon><infon key="name_1">surname:Jokaji;given-names:H</infon><infon key="name_2">surname:Saito;given-names:M</infon><infon key="name_3">surname:Uotani;given-names:C</infon><infon key="name_4">surname:Kumabashiri;given-names:I</infon><infon key="name_5">surname:Morishita;given-names:E</infon><infon key="name_6">surname:Yamazaki;given-names:M</infon><infon key="name_7">surname:Matsuda;given-names:T</infon><infon key="pub-id_pmid">1899963</infon><infon key="section_type">REF</infon><infon key="source">Am J Hematol</infon><infon key="type">ref</infon><infon key="volume">36</infon><infon key="year">1991</infon><offset>31233</offset><text>Change in plasma levels of tissue plasminogen activator/inhibitor  complex and active plasminogen activator inhibitor in patients with  disseminated intravascular coagulation.</text></passage><passage><infon key="fpage">381</infon><infon key="lpage">387</infon><infon key="name_0">surname:Sprengers;given-names:ED</infon><infon key="name_1">surname:Kluft;given-names:C</infon><infon key="section_type">REF</infon><infon key="source">Blood</infon><infon key="type">ref</infon><infon key="volume">2</infon><infon key="year">1987</infon><offset>31409</offset><text>Plasminogen activator inhibitors.</text></passage><passage><infon key="fpage">277</infon><infon key="lpage">290</infon><infon key="name_0">surname:Lijnen;given-names:HR</infon><infon key="name_1">surname:Collen;given-names:D</infon><infon key="pub-id_pmid">7549063</infon><infon key="section_type">REF</infon><infon key="source">Baillieres Clin Haematol</infon><infon key="type">ref</infon><infon key="volume">8</infon><infon key="year">1995</infon><offset>31443</offset><text>Mechanisms of physiological fibrinolysis.</text></passage><passage><infon key="fpage">295</infon><infon key="lpage">301</infon><infon key="name_0">surname:Baars;given-names:JW</infon><infon key="name_1">surname:de Boer;given-names:JP</infon><infon key="name_2">surname:Wagstaff;given-names:J</infon><infon key="name_3">surname:Roem;given-names:D</infon><infon key="name_4">surname:Eerenberg-Belmer;given-names:AJ</infon><infon key="name_5">surname:Nauta;given-names:J</infon><infon key="name_6">surname:Pinedo;given-names:HM</infon><infon key="name_7">surname:Hack;given-names:CE</infon><infon key="pub-id_pmid">1419810</infon><infon key="section_type">REF</infon><infon key="source">Br J Haematol</infon><infon key="type">ref</infon><infon key="volume">82</infon><infon key="year">1992</infon><offset>31485</offset><text>Interleukin-2 induces activation of coagulation and fibrinolysis:  resemblance to the changes seen during experimental endotoxemia.</text></passage><passage><infon key="section_type">FIG</infon><infon key="type">title_1</infon><offset>31617</offset><text>Figures and Tables</text></passage><passage><infon key="file">CC-5-2-088-1.jpg</infon><infon key="id">F1</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>31636</offset><text>Bedside-type artificial pancreas STG-22.</text></passage><passage><infon key="file">CC-5-2-088-2.jpg</infon><infon key="id">F2</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>31677</offset><text>Correlations between mMOF score and parameters related to coagulation 
and fibrinolysis. The mMOF score (mMOF score = MOF score - the points of 
coagulopathy of MOF score) was positively correlated with (a) the DIC 
score, (b) TAT and (d) tPA-PAI-1 complex, and (c) 
negatively correlated with PLT.</text></passage><passage><infon key="file">CC-5-2-088-3.jpg</infon><infon key="id">F3</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>31976</offset><text>Correlation between TM and MOF score. The MOF score was positively 
correlated with blood TM level.</text></passage><passage><infon key="file">CC-5-2-088-4.jpg</infon><infon key="id">F4</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>32076</offset><text>Correlations between TM and parameters related with coagulation and 
fibrinolysis. Blood TM levels were positively correlated with (a) the 
DIC score, (b) tPA-PAI-1 complex and (c) TAT, and (d) 
negatively correlated with PLT.</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>32303</offset><text>Primary diseases of the nine septic patients with glucose 
intolerance</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Patient&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;Age (years)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;Sex&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Diseases&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;
Prognosis&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;1&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;54&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;F&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ARDS (after panperitonitis due to perforation of the 
ileum)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;Alive&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;2&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;67&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;M&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ARDS (after panperitonitis due to NOMI)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;Alive&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;3&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;74&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;M&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ARDS (after panperitonitis due to perforation of the 
duodenum)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;Died&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;4&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;49&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;M&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ARDS (after panperitonitis due to necrotic 
cholecystitis)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;Alive&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;5&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;47&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;M&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ARDS (after the operation of acute subdural hematoma)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;Alive&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;6&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;59&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;M&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ARDS (after the operation of subarachnoideal hemorrhage)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;Alive&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;7&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;66&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;M&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Gangrene of lower extremity&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;
Alive&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;8&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;74&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;M&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Gangrene of lower extremity&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;
Alive&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;9&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;21&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;M&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Burn&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;Alive&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>32374</offset><text>Patient	Age (years)	Sex	Diseases		 	Prognosis	 	1	54	F	ARDS (after panperitonitis due to perforation of the 	 	ileum)	Alive	 	2	67	M	ARDS (after panperitonitis due to NOMI)	Alive	 	3	74	M	ARDS (after panperitonitis due to perforation of the 	 	duodenum)	Died	 	4	49	M	ARDS (after panperitonitis due to necrotic 	 	cholecystitis)	Alive	 	5	47	M	ARDS (after the operation of acute subdural hematoma)	Alive	 	6	59	M	ARDS (after the operation of subarachnoideal hemorrhage)	Alive	 	7	66	M	Gangrene of lower extremity		 	Alive	 	8	74	M	Gangrene of lower extremity		 	Alive	 	9	21	M	Burn	Alive	 	</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>32965</offset><text>ARDS, Acute respiratory distress syndrome; F, female; M, male; NOMI, 
nonocclusive mesenteric ischemia.</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>33069</offset><text>Multiple organ failure score calculated using the criteria proposed 
by the Japanese Association for Critical Care Medicine </text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Impaired organ&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Criteria&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;Points&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Impaired organ&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Criteria&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;Points&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Kidney&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Urine output &amp;lt;600 ml/day; 
or 50 mg/dl &amp;lt; BUN;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;
Digestive tract&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Hematemesis, melena; or ulcer;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;or 3-5 mg/dl creatinine&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;or blood transfusion greater than 2 U/day&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;5 mg/dl &amp;lt; creatinine; or 0 ml/h &amp;lt; 
CH&lt;sub&gt;2&lt;/sub&gt;O;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;bleeding from digestive tract with hypotension,&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;
2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;or 3.0% &amp;lt; FENa&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;or perforation, necrosis&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Lung&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;PaO&lt;sub&gt;2&lt;/sub&gt; &amp;lt;60 mmHg 
(room air); or 250 mmHg&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;
Brain&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;10-100 JCS, or 8-12 GCS&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;
1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;≤ PaO&lt;sub&gt;2&lt;/sub&gt;/FiO&lt;sub&gt;2&lt;/sub&gt; 
&amp;lt;350 mmHg; or 300-400 mmHg&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;A-aDO&lt;sub&gt;2&lt;/sub&gt; (FiO&lt;sub&gt;2&lt;/sub&gt; = 1.0); or 
20-30% Qs/Qt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;100&amp;lt;JCS, 
or 8&amp;lt;GCS, or convulsion with&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;or with respirator for more than 5 days&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;unconsciousness, or no auditory 
brain stem&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;
response, or brain death&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;PaO&lt;sub&gt;2&lt;/sub&gt;/FiO&lt;sub&gt;2&lt;/sub&gt; &amp;lt;250 mmHg; 
or 400 mmHg&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;&amp;lt; A-aDO&lt;sub&gt;2&lt;/sub&gt; (FiO&lt;sub&gt;2&lt;/sub&gt; = 
1.0); or 30%&amp;lt;Qs/Qt&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;DIC&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;20 μg/ml ≤ FDP; or platelet ≤ 80,000/μl;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;or 
fibrinogen ≤ 100 mg/dl; or exacerbation&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Liver&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;3.0-5.0 mg/dl bilirubin; or 100 
IU/l &amp;lt; s-GPT;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;of FDP, platelet, fibrinogen within 2 days&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;or 0.4-0.7 AKBR&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;(more than three times greater than or&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;
one-third of normal value), or with heparin&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;5.0 mg/dl &amp;lt; bilirubin; or AKBR &amp;lt; 
0.4&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;(≥ 50 
U/kg per day) or probable DIC&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Cardiovascular&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;10 mmHg &amp;lt; CVP, or 
major arrhythmia,&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;Definite DIC&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;or Forrester classification: peripheral 
vascular&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;resistance &amp;lt; 1000 dyne s/cm&lt;sup&gt;5&lt;/sup&gt;; 
or with inotropic&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;agents for more than 2 h&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;Forrester classification: with shock, or 
life&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;threatening arrythmia, or acute myocardial&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;infarction, or cardiac arrest, or major 
arrhythmia&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;with shock&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>33194</offset><text>Impaired organ	Criteria	Points	Impaired organ	Criteria	Points	 	Kidney	Urine output &lt;600 ml/day; 	 	or 50 mg/dl &lt; BUN;	1		 	Digestive tract	Hematemesis, melena; or ulcer;	1	 		or 3-5 mg/dl creatinine			or blood transfusion greater than 2 U/day		 		5 mg/dl &lt; creatinine; or 0 ml/h &lt; 	 	CH2O;	2		bleeding from digestive tract with hypotension,		 	2	 		or 3.0% &lt; FENa			or perforation, necrosis		 	Lung	PaO2 &lt;60 mmHg 	 	(room air); or 250 mmHg	1		 	Brain	10-100 JCS, or 8-12 GCS		 	1	 		≤ PaO2/FiO2 	 	&lt;350 mmHg; or 300-400 mmHg					 		A-aDO2 (FiO2 = 1.0); or 	 	20-30% Qs/Qt;			100&lt;JCS, 	 	or 8&lt;GCS, or convulsion with	2	 		or with respirator for more than 5 days			unconsciousness, or no auditory 	 	brain stem		 						 	response, or brain death		 		PaO2/FiO2 &lt;250 mmHg; 	 	or 400 mmHg	2				 		&lt; A-aDO2 (FiO2 = 	 	1.0); or 30%&lt;Qs/Qt		DIC	20 μg/ml ≤ FDP; or platelet ≤ 80,000/μl;	1	 					or 	 	fibrinogen ≤ 100 mg/dl; or exacerbation		 	Liver	3.0-5.0 mg/dl bilirubin; or 100 	 	IU/l &lt; s-GPT;	1		of FDP, platelet, fibrinogen within 2 days		 		or 0.4-0.7 AKBR	1		(more than three times greater than or		 						 	one-third of normal value), or with heparin		 		5.0 mg/dl &lt; bilirubin; or AKBR &lt; 	 	0.4	2		(≥ 50 	 	U/kg per day) or probable DIC		 	Cardiovascular	10 mmHg &lt; CVP, or 	 	major arrhythmia,	1		Definite DIC	2	 		or Forrester classification: peripheral 	 	vascular					 		resistance &lt; 1000 dyne s/cm5; 	 	or with inotropic					 		agents for more than 2 h					 		Forrester classification: with shock, or 	 	life	2				 		threatening arrythmia, or acute myocardial					 		infarction, or cardiac arrest, or major 	 	arrhythmia					 		with shock					 	</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>34857</offset><text>Judgement of probable disseminated intravascular coagulation 
(DIC)* and definite DIC* from Criteria of DIC proposed by 
the Ministry of Health and Welfare of Japan. 
A-aDO2, alveolar-arterial oxygen difference; AKBR, arterial ketone 
body ratio; BUN, blood urea nitrogen; CVP, central venous pressure; FDP, fibrin 
and fibrinogen degradation products; FENa, fractional excretion of sodium; GCS, 
Glasgow coma scale; JPS, Japan coma scale.</text></passage><passage><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>35297</offset><text>Criteria of disseminated intravascular coagulation (DIC) (The 
Ministry of Health and Welfare of Japan)</text></passage><passage><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Criteria&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;Points&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;1. Underlined disease&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;
(+)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;(-)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;
0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;2. Symptom&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;(1) Bleeding tendency&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(+)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;(-)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;
0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;(2) Symptom caused by organ dysfunction&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(+)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;(-)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;
0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;3. Laboratory data&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;(1) Serum FDP 
(μg/ml)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;40 ≤&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;20 ≤ &amp;lt; 40&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;10 ≤ &amp;lt; 20&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;10 &amp;gt;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;(2) Platelet (× 10&lt;sup&gt;3&lt;/sup&gt;
/μl)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;50 ≥&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;80 ≥ &amp;gt; 50&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;120 ≥ &amp;gt; 80&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;120&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;
0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;(3) Plasma fibrinogen (mg/dl)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;100 ≥&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;150 ≥ &amp;gt; 100&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;150 &amp;lt;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;(4) Prothrombin time/control&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1.67 ≤&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;1.25 ≤ &amp;lt; 1.67&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;1.25 &amp;gt;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;4. Supplemental data&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;(1) Detection of 
soluble fibrin monomer&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;(2) Increase of D-dimer&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;(3) Increase of thrombin-antithrombin 
complex&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;(4) Increase of plasmin-a&lt;sub&gt;2&lt;/sub&gt;-plasmin 
inhibitor complex&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;(5) Exacerbation of FDP, platelet, fibrinogen 
within several days&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;(6) Improvement of data with anticoagulant 
therapy&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Judgment&lt;sup&gt;*&lt;/sup&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;1. Definite DIC&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;(1) Patients who do 
not have leukemia, pernicious anemia, liver cirrhosis,&lt;/td&gt;&lt;td align=&quot;center&quot; colspan=&quot;2&quot;&gt;More than 7 or 6 points with&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;or who are not under cancer chemotherapy&lt;/td&gt;&lt;td align=&quot;center&quot; colspan=&quot;2&quot;&gt;more than two of supplemental data&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;(2) Patients who have leukemia, pernicious 
anemia, or who are&lt;/td&gt;&lt;td align=&quot;center&quot; colspan=&quot;2&quot;&gt;More than 4 or 3 points 
with&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;under cancer chemotherapy points for bleeding 
tendency and platelet&lt;/td&gt;&lt;td align=&quot;center&quot; colspan=&quot;2&quot;&gt;more than two of 
supplemental data&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;are not included&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;(3) Patients who have liver cirrhosis&lt;/td&gt;&lt;td align=&quot;center&quot; colspan=&quot;2&quot;&gt;More than 10 or 9 points with&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;center&quot; colspan=&quot;2&quot;&gt;more than two of 
supplemental data&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;2. Probable DIC&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;(1) Patients who do 
not have leukemia, pernicious anemia, liver cirrhosis,&lt;/td&gt;&lt;td align=&quot;center&quot; colspan=&quot;2&quot;&gt;6 points&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;or who are not under cancer chemotherapy&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;(2) Patients who have leukemia, pernicious 
anemia, or who are under&lt;/td&gt;&lt;td align=&quot;center&quot; colspan=&quot;2&quot;&gt;3 points&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;cancer chemotherapy points for bleeding 
tendency and platelet are not included&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;(3) Patients who have liver cirrhosis&lt;/td&gt;&lt;td align=&quot;center&quot; colspan=&quot;2&quot;&gt;9 points&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>35401</offset><text>Criteria			Points	 	1. Underlined disease			 	(+)	1	 			(-)		 	0	 	2. Symptom	(1) Bleeding tendency	(+)	1	 			(-)		 	0	 		(2) Symptom caused by organ dysfunction	(+)	1	 			(-)		 	0	 	3. Laboratory data	(1) Serum FDP 	 	(μg/ml)	40 ≤	3	 			20 ≤ &lt; 40	2	 			10 ≤ &lt; 20	1	 			10 &gt;	0	 		(2) Platelet (× 103	 	/μl)	50 ≥	3	 			80 ≥ &gt; 50	2	 			120 ≥ &gt; 80	1	 			120		 	0	 		(3) Plasma fibrinogen (mg/dl)	100 ≥	2	 			150 ≥ &gt; 100	1	 			150 &lt;	0	 		(4) Prothrombin time/control	1.67 ≤	2	 			1.25 ≤ &lt; 1.67	1	 			1.25 &gt;	0	 	4. Supplemental data	(1) Detection of 	 	soluble fibrin monomer			 		(2) Increase of D-dimer			 		(3) Increase of thrombin-antithrombin 	 	complex			 		(4) Increase of plasmin-a2-plasmin 	 	inhibitor complex			 		(5) Exacerbation of FDP, platelet, fibrinogen 	 	within several days			 		(6) Improvement of data with anticoagulant 	 	therapy			 	Judgment*				 	1. Definite DIC	(1) Patients who do 	 	not have leukemia, pernicious anemia, liver cirrhosis,	More than 7 or 6 points with	 		or who are not under cancer chemotherapy	more than two of supplemental data	 		(2) Patients who have leukemia, pernicious 	 	anemia, or who are	More than 4 or 3 points 	 	with	 		under cancer chemotherapy points for bleeding 	 	tendency and platelet	more than two of 	 	supplemental data	 		are not included			 		(3) Patients who have liver cirrhosis	More than 10 or 9 points with	 			more than two of 	 	supplemental data	 	2. Probable DIC	(1) Patients who do 	 	not have leukemia, pernicious anemia, liver cirrhosis,	6 points	 		or who are not under cancer chemotherapy			 		(2) Patients who have leukemia, pernicious 	 	anemia, or who are under	3 points	 		cancer chemotherapy points for bleeding 	 	tendency and platelet are not included			 		(3) Patients who have liver cirrhosis	9 points	 	</text></passage><passage><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>37214</offset><text>*Exclusion: this DIC criteria cannot be applied for 
neonates, pregnant woman, and patients with fulminant hepatitis. FDP, fibrin 
and fibrinogen degradation products.</text></passage><passage><infon key="file">T4.xml</infon><infon key="id">T4</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>37382</offset><text>Blood glucose control and measurements of glucose tolerance by 
means of artificial pancreas</text></passage><passage><infon key="file">T4.xml</infon><infon key="id">T4</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;Daily mean blood glucose levels (mg/dl)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;Mean &lt;italic&gt;M&lt;/italic&gt; values (mg/kg per min)&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;First measurement&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;183 ± 32 
(&lt;italic&gt;n&lt;/italic&gt; = 8)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4.4 ± 1.4 (&lt;italic&gt;n&lt;/italic&gt; = 7)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Second measurement&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;147 ± 26 
(&lt;italic&gt;n&lt;/italic&gt; = 9)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4.7 ± 1.6 (&lt;italic&gt;n&lt;/italic&gt; = 8)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Total&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;164 ± 34 (&lt;italic&gt;n&lt;/italic&gt; = 
17)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4.6 ± 1.5 (&lt;italic&gt;n&lt;/italic&gt; = 15)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>37475</offset><text>	Daily mean blood glucose levels (mg/dl)	Mean M values (mg/kg per min)	 	First measurement	183 ± 32 	 	(n = 8)	4.4 ± 1.4 (n = 7)	 	Second measurement	147 ± 26 	 	(n = 9)	4.7 ± 1.6 (n = 8)	 	Total	164 ± 34 (n = 	 	17)	4.6 ± 1.5 (n = 15)	 	</text></passage><passage><infon key="file">T4.xml</infon><infon key="id">T4</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>37720</offset><text>The first measurement was performed within 3 days after admission, 
and the second measurement was performed 1 week after the first measurement.</text></passage><passage><infon key="file">T5.xml</infon><infon key="id">T5</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>37865</offset><text>No significant correlations between glucose tolerance and blood 
stress related hormone levels: correlation coefficient (r) between the 
M value and hormones</text></passage><passage><infon key="file">T5.xml</infon><infon key="id">T5</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;Normal range&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;
Mean&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;&lt;italic&gt;r&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&lt;italic&gt;P&lt;/italic&gt;&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Adrenaline (ng/ml)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;≤ 0.17&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.11 ± 0.10&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 
18)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.17&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.55&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 15)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Noradrenaline (ng/ml)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.15-5.7&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.79 ± 0.74&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 
18)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.15&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.60&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 15)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Dopamine (ng/ml)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;≤ 0.03&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;19 ± 41&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 
18)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.20&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.48&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 15)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Growth hormone (ng/ml)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.28-8.70&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4.7 ± 5.2&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 
18)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.45&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.09&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 15)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Glucagon (pg/ml)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;23-197&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;234 ± 156&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 18)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.39&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.17&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 14)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Cortisol (μg/dl)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;5.6-21.3&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;33 ± 42&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 
18)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.10&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.73&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 15)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;ACTH (pg/ml)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;≤ 60&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;28 ± 19&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 18)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.05&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.87&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 15)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;TSH (μU/ml)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.5-4.8&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1.1 ± 1.6&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 17)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.49&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.08&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 14)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;T&lt;sub&gt;3&lt;/sub&gt; (ng/dl)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;80-180&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;82 ± 30&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 17)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.05&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.87&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 14)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Free T&lt;sub&gt;3&lt;/sub&gt; (pg/ml)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;
2.5-4.5&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2.2 ± 0.7&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;
n&lt;/italic&gt; = 17)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.10&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 
0.74&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 14)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;T&lt;sub&gt;4&lt;/sub&gt; (μg/dl)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;
5.0-13.7&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;9.4 ± 4.2&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;
n&lt;/italic&gt; = 17)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.09&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 
0.76&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 14)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Free T&lt;sub&gt;4&lt;/sub&gt; (ng/dl)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;
0.8-1.9&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1.4 ± 0.6&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;
n&lt;/italic&gt; = 17)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.11&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 
0.71&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 14)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>38023</offset><text>	Normal range		 	Mean		r	P		 	Adrenaline (ng/ml)	≤ 0.17	0.11 ± 0.10	(n = 	 	18)	-0.17	&lt; 0.55	(n = 15)	 	Noradrenaline (ng/ml)	0.15-5.7	0.79 ± 0.74	(n = 	 	18)	0.15	&lt; 0.60	(n = 15)	 	Dopamine (ng/ml)	≤ 0.03	19 ± 41	(n = 	 	18)	0.20	&lt; 0.48	(n = 15)	 	Growth hormone (ng/ml)	0.28-8.70	4.7 ± 5.2	(n = 	 	18)	-0.45	&lt; 0.09	(n = 15)	 	Glucagon (pg/ml)	23-197	234 ± 156	(n = 18)	0.39	&lt; 0.17	(n = 14)	 	Cortisol (μg/dl)	5.6-21.3	33 ± 42	(n = 	 	18)	-0.10	&lt; 0.73	(n = 15)	 	ACTH (pg/ml)	≤ 60	28 ± 19	(n = 18)	-0.05	&lt; 0.87	(n = 15)	 	TSH (μU/ml)	0.5-4.8	1.1 ± 1.6	(n = 17)	0.49	&lt; 0.08	(n = 14)	 	T3 (ng/dl)	80-180	82 ± 30	(n = 17)	-0.05	&lt; 0.87	(n = 14)	 	Free T3 (pg/ml)		 	2.5-4.5	2.2 ± 0.7	(	 	n = 17)	-0.10	&lt; 	 	0.74	(n = 14)	 	T4 (μg/dl)		 	5.0-13.7	9.4 ± 4.2	(	 	n = 17)	0.09	&lt; 	 	0.76	(n = 14)	 	Free T4 (ng/dl)		 	0.8-1.9	1.4 ± 0.6	(	 	n = 17)	0.11	&lt; 	 	0.71	(n = 14)	 	</text></passage><passage><infon key="file">T5.xml</infon><infon key="id">T5</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>38911</offset><text>ACTH, Adrenocorticotrophic hormone; TSH, thyroid stimulating hormone; 
T3, triiodothyronine; T4 = thyroxine.</text></passage><passage><infon key="file">T6.xml</infon><infon key="id">T6</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>39020</offset><text>No significant correlations between glucose tolerance and multiple 
organ dysfunction syndrome, coagulopathy: correlation coefficient (r) 
between the M value and the multiple organ failure (MOF) 
score/parameters related with coagulopathy</text></passage><passage><infon key="file">T6.xml</infon><infon key="id">T6</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;Normal range&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;
Mean&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;&lt;italic&gt;r&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&lt;italic&gt;P&lt;/italic&gt;&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;MOF score&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;4.6 ± 
1.5&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 15)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.20&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.48&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 15)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;DIC score&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;4.0 ± 
1.8&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 18)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.32&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.25&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 15)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;PLT (/μl)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;150,000-280,000&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;188,000 ± 123,000&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;
n&lt;/italic&gt; = 18)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.39&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 
0.15&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 15)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;FDP (μg/ml)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 10&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;14 ± 15&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 18)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.49&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.06&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 15)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;PT ratio&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 1.25&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1.3 ± 0.10&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 16)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.02&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.95&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 13)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Fibrinogen (mg/dl)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;150-350&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;500 ± 154&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 18)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.23&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.42&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 15)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;TAT (ng/ml)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;≤ 3.0&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;13.2 ± 13.0&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 18)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.34&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.22&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 15)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;PIC (μg/ml)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;≤ 0.8&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1.2 ± 0.7&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 18)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.27&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.34&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 15)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;D-Dimer (ng/ml)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;≤ 150&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;750 ± 630&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 18)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.43&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.11&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 15)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Plasminogen (%)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;75-125&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;80 ± 23&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 18)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.25&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.37&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 15)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;AT-III(%)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;70-120&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;94 ± 28&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 13)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.25&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.47&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 11)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Protein C activity (%)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;55-140&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;75 ± 43&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 
18)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.44&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.10&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 15)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Protein C antigen (%)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;70-150&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;92 ± 51&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 18)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.47&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.08&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 15)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Protein S activity (%)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;60-150&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;72 ± 18&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 
18)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.42&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.12&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 15)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Protein S antigen (%)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;65-135&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;83 ± 24&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 18)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.42&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.12&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 15)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;PAI-1 activity (U/ml)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;12-15&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;5.3 ± 3.4&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 13)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.55&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.10&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 10)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;PAI-1 antigen (ng/ml)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;≤ 50&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;120 ± 86&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 
18)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.22&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.44&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 15)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;tPA-PAI-1 complex (ng/ml)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;≤ 
11&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;26 ± 18&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 
18)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.27&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.34&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 15)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>39260</offset><text>	Normal range		 	Mean		r	P		 	MOF score		4.6 ± 	 	1.5	(n = 15)	0.20	&lt; 0.48	(n = 15)	 	DIC score		4.0 ± 	 	1.8	(n = 18)	0.32	&lt; 0.25	(n = 15)	 	PLT (/μl)	150,000-280,000	188,000 ± 123,000	(	 	n = 18)	0.39	&lt; 	 	0.15	(n = 15)	 	FDP (μg/ml)	&lt; 10	14 ± 15	(n = 18)	0.49	&lt; 0.06	(n = 15)	 	PT ratio	&lt; 1.25	1.3 ± 0.10	(n = 16)	-0.02	&lt; 0.95	(n = 13)	 	Fibrinogen (mg/dl)	150-350	500 ± 154	(n = 18)	-0.23	&lt; 0.42	(n = 15)	 	TAT (ng/ml)	≤ 3.0	13.2 ± 13.0	(n = 18)	0.34	&lt; 0.22	(n = 15)	 	PIC (μg/ml)	≤ 0.8	1.2 ± 0.7	(n = 18)	0.27	&lt; 0.34	(n = 15)	 	D-Dimer (ng/ml)	≤ 150	750 ± 630	(n = 18)	0.43	&lt; 0.11	(n = 15)	 	Plasminogen (%)	75-125	80 ± 23	(n = 18)	0.25	&lt; 0.37	(n = 15)	 	AT-III(%)	70-120	94 ± 28	(n = 13)	0.25	&lt; 0.47	(n = 11)	 	Protein C activity (%)	55-140	75 ± 43	(n = 	 	18)	0.44	&lt; 0.10	(n = 15)	 	Protein C antigen (%)	70-150	92 ± 51	(n = 18)	0.47	&lt; 0.08	(n = 15)	 	Protein S activity (%)	60-150	72 ± 18	(n = 	 	18)	0.42	&lt; 0.12	(n = 15)	 	Protein S antigen (%)	65-135	83 ± 24	(n = 18)	0.42	&lt; 0.12	(n = 15)	 	PAI-1 activity (U/ml)	12-15	5.3 ± 3.4	(n = 13)	0.55	&lt; 0.10	(n = 10)	 	PAI-1 antigen (ng/ml)	≤ 50	120 ± 86	(n = 	 	18)	0.22	&lt; 0.44	(n = 15)	 	tPA-PAI-1 complex (ng/ml)	≤ 	 	11	26 ± 18	(n = 	 	18)	0.27	&lt; 0.34	(n = 15)	 	</text></passage><passage><infon key="file">T6.xml</infon><infon key="id">T6</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>40511</offset><text>AT-III, antithrombin-III; DIC, disseminated intravascular 
coagulation; FDP, fibrin and fibrinogen degradation products; PAI-1, 
plasminogen activator inhibitor-1; PIC, α2 plasmin 
inhibitor-plasmin complex; PLT, platelet count; PT, prothrombin time; TAT, 
thrombin-antithrombin complex; tPA, tissue plasminogen activator.</text></passage><passage><infon key="file">T7.xml</infon><infon key="id">T7</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>40838</offset><text>Correlation coefficients (r) between multiple organ 
failure score and parameters related to coagulation and fibrinolysis</text></passage><passage><infon key="file">T7.xml</infon><infon key="id">T7</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;&lt;italic&gt;r&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&lt;italic&gt;
P&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&lt;italic&gt;n&lt;/italic&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;DIC score&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.75&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.002&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;TAT&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.72&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;
&amp;lt; 0.002&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;tPA-PAI-1 complex&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.69&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.002&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;PLT&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.68&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;
&amp;lt; 0.002&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Protein S activity&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.48&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.04&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Plasminogen&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.43&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 008&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Protein C activity&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.41&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.09&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;D-Dimer&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.38&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.12&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;FDP&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.37&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;
&amp;lt; 0.13&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Protein C antigen&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.31&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.22&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Protein S antigen&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.25&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.32&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;PAI-1 activity&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.25&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.42&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;13&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;PT ratio&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.23&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.40&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;16&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;AT-III&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.22&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.48&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;13&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;PIC&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.2&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;
&amp;lt; 0.43&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;PAI-1 antigen&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.19&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.46&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Fibrinogen&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.000,09&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 1.0&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>40960</offset><text>	r		 	P	n	 	DIC score	0.75	&lt; 0.002	18	 	TAT	0.72		 	&lt; 0.002	18	 	tPA-PAI-1 complex	0.69	&lt; 0.002	18	 	PLT	-0.68		 	&lt; 0.002	18	 	Protein S activity	-0.48	&lt; 0.04	18	 	Plasminogen	-0.43	&lt; 008	18	 	Protein C activity	-0.41	&lt; 0.09	18	 	D-Dimer	0.38	&lt; 0.12	18	 	FDP	0.37		 	&lt; 0.13	18	 	Protein C antigen	-0.31	&lt; 0.22	18	 	Protein S antigen	-0.25	&lt; 0.32	18	 	PAI-1 activity	-0.25	&lt; 0.42	13	 	PT ratio	-0.23	&lt; 0.40	16	 	AT-III	0.22	&lt; 0.48	13	 	PIC	0.2		 	&lt; 0.43	18	 	PAI-1 antigen	0.19	&lt; 0.46	18	 	Fibrinogen	0.000,09	&lt; 1.0	18	 	</text></passage><passage><infon key="file">T7.xml</infon><infon key="id">T7</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>41481</offset><text>AT, Antithrombin; DIC, disseminated intravascular coagulation; FDP, 
fibrin and fibrinogen degradation products; PAI-1, plasminogen activator 
inhibitor-1; PIC, α2 plasmin inhibitor-plasmin complex; PLT, 
platelet count; PT, prothrombin time; TAT, thrombin-antithrombin complex; tPA, 
tissue plasminogen activator.</text></passage><passage><infon key="file">T8.xml</infon><infon key="id">T8</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>41800</offset><text>Correlation coefficients (r) between modified multiple 
organ failure (mMOF) score* and parameters related to coagulation 
and fibrinolysis</text></passage><passage><infon key="file">T8.xml</infon><infon key="id">T8</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;&lt;italic&gt;r&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&lt;italic&gt;
P&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&lt;italic&gt;n&lt;/italic&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;DIC score&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.66&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.002&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;TAT&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.69&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;
&amp;lt; 0.002&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;PLT&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.65&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;
&amp;lt; 0.003&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;tPA-PAI-1 complex&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.62&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.005&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Protein S activity&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.44&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.07&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Protein C activity&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.43&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.08&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Plasminogen&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.42&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.08&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Protein C antigen&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.32&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.20&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;D-Dimer&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.3&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.23&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;AT-III&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.24&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.46&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;13&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Protein S antigen&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.22&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.38&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;PAI-1 activity&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.21&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.50&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;13&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;PT ratio&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.18&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.51&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;16&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;PAI-1 antigen&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.18&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.48&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;PIC&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.16&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;
&amp;lt; 0.54&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Fibrinogen&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.000,03&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 1.0&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>41940</offset><text>	r		 	P	n	 	DIC score	0.66	&lt; 0.002	18	 	TAT	0.69		 	&lt; 0.002	18	 	PLT	-0.65		 	&lt; 0.003	18	 	tPA-PAI-1 complex	0.62	&lt; 0.005	18	 	Protein S activity	-0.44	&lt; 0.07	18	 	Protein C activity	-0.43	&lt; 0.08	18	 	Plasminogen	-0.42	&lt; 0.08	18	 	Protein C antigen	-0.32	&lt; 0.20	18	 	D-Dimer	0.3	&lt; 0.23	18	 	AT-III	0.24	&lt; 0.46	13	 	Protein S antigen	-0.22	&lt; 0.38	18	 	PAI-1 activity	-0.21	&lt; 0.50	13	 	PT ratio	-0.18	&lt; 0.51	16	 	PAI-1 antigen	0.18	&lt; 0.48	18	 	PIC	0.16		 	&lt; 0.54	18	 	Fibrinogen	0.000,03	&lt; 1.0	18	 	</text></passage><passage><infon key="file">T8.xml</infon><infon key="id">T8</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>42438</offset><text>* mMOF score = MOF score - points of coagulopathy of the 
MOF score. AT, Antithrombin; DIC, disseminated intravascular coagulation; 
PAI-1, plasminogen activator inhibitor-1; PIC, α2 plasmin 
inhibitor-plasmin complex; PLT, platelet count; PT, prothrombin time; TAT, 
thrombin-antithrombin complex; tPA, tissue plasminogen activator.</text></passage><passage><infon key="file">T9.xml</infon><infon key="id">T9</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>42776</offset><text>Correlation coefficients (r) between thrombomodulin (TM) 
and multiple organ failure (MOF) score, parameters related to coagulation and 
fibrinolysis*</text></passage><passage><infon key="file">T9.xml</infon><infon key="id">T9</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;&lt;italic&gt;r&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&lt;italic&gt;
P&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&lt;italic&gt;n&lt;/italic&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;MOF score&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.92&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.002&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;17&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;DIC score&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.80&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.002&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;17&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;tPA-PAI-1 complex&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.85&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.002&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;17&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;TAT&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.85&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;
&amp;lt; 0.002&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;17&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;PLT&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.58&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;
&amp;lt; 0.01&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;17&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;FDP&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.50&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;
&amp;lt; 0.04&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;17&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;D-Dimer&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.48&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.05&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;17&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;PAI-1 antigen&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.40&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.11&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;17&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Protein C activity&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.38&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.13&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;17&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Protein S activity&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.36&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.16&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;17&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;PIC&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.33&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;
&amp;lt; 0.20&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;17&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Fibrinogen&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.31&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.23&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;17&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Plasminogen&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.31&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.23&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;17&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Protein C antigen&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.3&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.25&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;17&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;AT-III&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.27&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.41&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;12&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;PT ratio&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.25&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.38&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;15&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Protein S antigen&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.15&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.57&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;17&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;PAI-1 activity&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.04&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.90&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;12&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>42927</offset><text>	r		 	P	n	 	MOF score	0.92	&lt; 0.002	17	 	DIC score	0.80	&lt; 0.002	17	 	tPA-PAI-1 complex	0.85	&lt; 0.002	17	 	TAT	0.85		 	&lt; 0.002	17	 	PLT	-0.58		 	&lt; 0.01	17	 	FDP	0.50		 	&lt; 0.04	17	 	D-Dimer	0.48	&lt; 0.05	17	 	PAI-1 antigen	0.40	&lt; 0.11	17	 	Protein C activity	-0.38	&lt; 0.13	17	 	Protein S activity	-0.36	&lt; 0.16	17	 	PIC	0.33		 	&lt; 0.20	17	 	Fibrinogen	-0.31	&lt; 0.23	17	 	Plasminogen	-0.31	&lt; 0.23	17	 	Protein C antigen	-0.3	&lt; 0.25	17	 	AT-III	0.27	&lt; 0.41	12	 	PT ratio	-0.25	&lt; 0.38	15	 	Protein S antigen	-0.15	&lt; 0.57	17	 	PAI-1 activity	-0.04	&lt; 0.90	12	 	</text></passage><passage><infon key="file">T9.xml</infon><infon key="id">T9</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>43474</offset><text>* Mean of TM, 7.3 ± 4.2 FU/ml (n = 17); 
normal range, ≤ 4.5. AT-III, antithrombin-III; DIC, disseminated 
intravascular coagulation; FDP, fibrin and fibrinogen degradation products; 
PAI-1, plasminogen activator inhibitor-1; PIC, α2 plasmin 
inhibitor-plasmin complex; PLT, platelet count; PT, prothrombin time; TAT, 
thrombin-antithrombin complex; tPA, tissue plasminogen activator.</text></passage><passage><infon key="file">T10.xml</infon><infon key="id">T10</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>43865</offset><text>Correlation coefficients (r)between the tissue plasminogen 
activator-plasminogen activator inhibitor-1 (tPA-PAI-1) complex and other 
parameters related to coagulation and fibrinolysis</text></passage><passage><infon key="file">T10.xml</infon><infon key="id">T10</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;&lt;italic&gt;r&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;P&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&lt;italic&gt;n&lt;/italic&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;DIC score&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.74&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.002&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;TAT&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.85&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;
&amp;lt; 0.002&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;PAI-1 antigen&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.60&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.007&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;PLT&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.49&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;
&amp;lt; 0.04&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Protein C activity&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.39&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.11&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;PT ratio&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.37&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.16&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;D-Dimer&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.36&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.14&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;FDP&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.36&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;
&amp;lt; 0.14&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Protein S antigen&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.34&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.17&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Protein C antigen&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.33&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.18&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Plasminogen&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.31&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.22&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;PIC&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.30&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;
&amp;lt;0.23&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Fibrinogen&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.10&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.70&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;AT-III&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.035&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.90&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;13&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;PAI-1 activity&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;-0.014&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&amp;lt; 0.98&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;13&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>44051</offset><text>	r	P	n	 	DIC score	0.74	&lt; 0.002	18	 	TAT	0.85		 	&lt; 0.002	18	 	PAI-1 antigen	0.60	&lt; 0.007	18	 	PLT	-0.49		 	&lt; 0.04	18	 	Protein C activity	-0.39	&lt; 0.11	18	 	PT ratio	-0.37	&lt; 0.16	18	 	D-Dimer	0.36	&lt; 0.14	18	 	FDP	0.36		 	&lt; 0.14	18	 	Protein S antigen	-0.34	&lt; 0.17	18	 	Protein C antigen	-0.33	&lt; 0.18	18	 	Plasminogen	-0.31	&lt; 0.22	18	 	PIC	0.30		 	&lt;0.23	18	 	Fibrinogen	-0.10	&lt; 0.70	18	 	AT-III	0.035	&lt; 0.90	13	 	PAI-1 activity	-0.014	&lt; 0.98	13	 	</text></passage><passage><infon key="file">T10.xml</infon><infon key="id">T10</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>44497</offset><text>AT-III, antithrombin-III; DIC, disseminated intravascular 
coagulation; FDP, fibrin and fibrinogen degradation products; PIC, α
2 plasmin inhibitor-plasmin complex; PLT, platelet count; PT, prothrombin 
time; TAT, thrombin-antithrombin complex.</text></passage></document></collection>
